Sensei Biotherapeutics is a technology company.
Sensei Biotherapeutics has raised $59.0M across 2 funding rounds.
Sensei Biotherapeutics has raised $59.0M in total across 2 funding rounds.
Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing next-generation immunotherapies, primarily conditionally active antibodies that function selectively in the tumor microenvironment to enhance anti-cancer immune responses.[1][2][3][4] Its key platforms include ImmunoPhage, which uses bacteriophage to target tumor-associated antigens in personalized yet off-the-shelf cancer treatments like the preclinical SNS-401-NG for Merkel Cell Carcinoma, and TMAb, featuring human monoclonal antibodies and alpaca-derived nanobodies such as SNS-VISTA targeting the VISTA immune checkpoint.[1][2] The company serves cancer patients by addressing unmet needs in immunotherapy, with a pipeline of investigational therapies traded publicly as NASDAQ: SNSE, demonstrating growth through platform scalability and manufacturing efficiency.[1][3][4]
Sensei Biotherapeutics emerged as a biopharmaceutical innovator focused on immuno-oncology, though specific founding details like exact year or original founders are not detailed in available sources; it has evolved into a clinical-stage entity with deep expertise in phage-based and antibody platforms.[1][3] The company's idea stems from leveraging the immune system's natural mechanisms—such as bacteriophage to engage immune responses and tumor-selective antibodies—to overcome limitations in traditional cancer treatments.[1][2][4] Pivotal moments include advancing ImmunoPhage's Phortress™ library for multi-antigen targeting and TMAb candidates into preclinical and lead generation stages, supported by a leadership team including business leaders like those with MBAs from Carnegie Mellon and biophysics backgrounds, alongside board members such as James Peyer, Ph.D., founder of longevity biotech firm Cambrian Biopharma.[1][2]
Sensei rides the immuno-oncology wave, capitalizing on advances in tumor microenvironment modulation and phage-based vaccines amid rising demand for precision cancer therapies.[1][2][4] Timing aligns with maturing checkpoint inhibitors and biologics, where market forces like scalable manufacturing needs and personalized medicine favor its off-the-shelf yet adaptable platforms.[1][3] As a clinical-stage player (NASDAQ: SNSE), it influences the biotech ecosystem by pioneering conditionally active antibodies, potentially expanding options for hard-to-treat cancers like Merkel Cell Carcinoma and contributing to broader immunotherapy innovation.[1][3][4]
Sensei Biotherapeutics is poised to advance its pipeline, with preclinical assets like SNS-401-NG and SNS-VISTA potentially entering clinics, driven by immunotherapy trends and immune checkpoint discoveries.[1][2] Evolving regulations, AI-aided drug design, and partnerships could accelerate growth, amplifying its role in cancer treatment ecosystems. As a nimble clinical-stage biotech, its tumor-selective focus positions it to shape next-gen therapies, building on its immune-inspired platforms for sustained impact.[1][4]
Sensei Biotherapeutics has raised $59.0M in total across 2 funding rounds.
Sensei Biotherapeutics's investors include Catalio Capital, Helium-3 Ventures, Inveready Technology Investment Group, MMC Ventures, Platanus Ventures, Presight Capital, Valar Ventures, Christian Woolfenden, Matt Bellamy, Richard Fearn.
Sensei Biotherapeutics has raised $59.0M across 2 funding rounds. Most recently, it raised $30.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $30.0M Series B | Catalio Capital, Helium-3 Ventures, Inveready Technology Investment Group, MMC Ventures, Platanus Ventures, Presight Capital, Valar Ventures, Christian Woolfenden, Matt Bellamy, Richard Fearn | |
| Oct 1, 2020 | $29.0M Series A | Helium-3 Ventures, MMC Ventures, Platanus Ventures, Presight Capital, Valar Ventures, Christian Woolfenden, Matt Bellamy, Richard Fearn |